"First, we will continue to strengthen the press offensive. Through the academic journals and industry media we control, we will question the controllability, reproducibility, and long-term safety of this biopharmaceutical developed outside internationally recognized standards and platforms. Emphasize the significant risks that unverified technological paths may pose, and plant seeds of doubt in the minds of scientists and the public. Let it take root and grow."
"Second, launch an intellectual property assault. Utilize all our patent lawyers and intelligence networks to conduct a comprehensive analysis of 'X-2' and its related technologies. Identify any possible entry point, even if only tenuously related to our existing patents, and file patent lawsuits globally. Even if we can't win, we must slow their progress and increase their costs."
